0.71
9.23%
+0.06
ThermoGenesis Holdings Inc stock is currently priced at $0.71, with a 24-hour trading volume of 3,476.
It has seen a +9.23% increased in the last 24 hours and a -12.24% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.6617 pivot point. If it approaches the $0.7667 resistance level, significant changes may occur.
ThermoGenesis Holdings Inc Stock (THMO) Financials Data
ThermoGenesis Holdings Inc (THMO) Revenue 2024
THMO reported a revenue (TTM) of $9.71 million for the quarter ending September 30, 2023, a -4.99% decline year-over-year.
ThermoGenesis Holdings Inc (THMO) Net Income 2024
THMO net income (TTM) was -$14.39 million for the quarter ending September 30, 2023, a -37.19% decrease year-over-year.
ThermoGenesis Holdings Inc (THMO) Cash Flow 2024
THMO recorded a free cash flow (TTM) of -$4.49 million for the quarter ending September 30, 2023, a +33.57% increase year-over-year.
ThermoGenesis Holdings Inc (THMO) Earnings per Share 2024
THMO earnings per share (TTM) was -$9.7301 for the quarter ending September 30, 2023, a +67.97% growth year-over-year.
ThermoGenesis Holdings Inc Stock (THMO) Latest News
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Compass Minerals International Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Disney Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Container Store Group Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Certara, Inc. (CERT) Q3 Earnings Meet Estimates
Zacks Investment Research
About ThermoGenesis Holdings Inc
ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The company manufactures and markets AXP II Automated Cell Separation System, an automated cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. It offers PXP Point-of-Care System, an automated sterile system for the automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; PXP-LAVARE System, an automated system designed to wash, re-suspend, and volume reduce cell suspensions; PXP-1000 System, an automated system for fast and reproducible separation of multiple cellular components from blood with minimal red blood cell contamination; and X-Series products, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, X-Mini for small scale cell purification, and X-BACS System under development for large scale cell purification. It also provides CAR-TXpress Platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing, and controls needs. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.
Cap:
|
Volume (24h):